| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.68 | 0.02 (+0.14%) | 9.11 - 15.34 | 13.0 thousand (Below Avg) |
Market data as of 3:56PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 14.56 |
|---|---|
| Previous Close | 14.66 |
| Day's Range | 14.51 - 14.70 |
| Market Cap | 181.1M |
| Avg Volume (10 Day) | 29.5K |
| Price/Earnings (Trailing 12 Mo.) | 47.3x |
| Earnings Per Share (Trailing 12 Mo.) | 0.31 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Rochester Medical Reports Fiscal 2013 Second Quarter Results
PR Newswire - Thursday 04/25/2013 4:00 PM ET
| ROCM | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 14.16% | |
| Net Income Growth (1yr) | 141.50% | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 2.11% | |
| Price/Sales | 2.72 |
| Company | Last | Change |
|---|---|---|
| Utah Medical Products Inc | 48.00 | -0.08% |
| Mesa Laboratories Inc | 52.26 | -0.36% |
| Alphatec Holdings Inc | 1.95 | +0.52% |
| AtriCure Inc | 9.29 | -0.11% |
| Harvard Bioscience Inc | 5.12 | -0.78% |
Data is delayed by at least 15 min.